Rebif Promos Need More Risk Information, FDA Says, Citing Web, Print Ads
Executive Summary
Serono needs to include more risk information in its Rebif promotions, FDA said in citing website and journal advertisements for the multiple sclerosis product
You may also be interested in...
Websites Must Be Submitted To FDA Like Other Ads, Agency Reminds Industry
A recent theme of FDA advertising enforcement letters is a reminder to companies to submit promotional websites to the agency as they would any other marketing materials
Websites Must Be Submitted To FDA Like Other Ads, Agency Reminds Industry
A recent theme of FDA advertising enforcement letters is a reminder to companies to submit promotional websites to the agency as they would any other marketing materials
Biogen Avonex Patient Satisfaction Claim Draws Objection From FDA
FDA is directing Biogen to stop making a patient satisfaction claim that the agency believes is misleading